MX353186B - Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide. - Google Patents

Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.

Info

Publication number
MX353186B
MX353186B MX2014012257A MX2014012257A MX353186B MX 353186 B MX353186 B MX 353186B MX 2014012257 A MX2014012257 A MX 2014012257A MX 2014012257 A MX2014012257 A MX 2014012257A MX 353186 B MX353186 B MX 353186B
Authority
MX
Mexico
Prior art keywords
rheumatoid arthritis
methods
diagnosing
treating
monitoring rheumatoid
Prior art date
Application number
MX2014012257A
Other languages
English (en)
Spanish (es)
Inventor
Flavius Martin
Jr Glynn Dennis
Michael J Townsend
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX353186B publication Critical patent/MX353186B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rehabilitation Therapy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
MX2014012257A 2009-09-03 2010-09-02 Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide. MX353186B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27594809P 2009-09-03 2009-09-03
US25242409P 2009-10-16 2009-10-16
PCT/US2010/047734 WO2011028945A1 (en) 2009-09-03 2010-09-02 Methods for treating, diagnosing, and monitoring rheumatoid arthritis

Publications (1)

Publication Number Publication Date
MX353186B true MX353186B (es) 2018-01-05

Family

ID=43625246

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014012257A MX353186B (es) 2009-09-03 2010-09-02 Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
MX2012002766A MX2012002766A (es) 2009-09-03 2010-09-02 Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012002766A MX2012002766A (es) 2009-09-03 2010-09-02 Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.

Country Status (11)

Country Link
US (2) US8728730B2 (enExample)
EP (2) EP2473637B1 (enExample)
JP (3) JP5996429B2 (enExample)
KR (1) KR20120104517A (enExample)
CN (2) CN107385034B (enExample)
BR (1) BR112012004777A2 (enExample)
CA (1) CA2772929A1 (enExample)
IN (1) IN2012DN02485A (enExample)
MX (2) MX353186B (enExample)
RU (2) RU2539112C2 (enExample)
WO (1) WO2011028945A1 (enExample)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54450B1 (sr) 2003-11-05 2016-06-30 Roche Glycart Ag Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
US8645166B2 (en) 2007-07-16 2014-02-04 Russell W. Bessette System and method for scoring illness complexity to predict healthcare cost
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
IN2012DN02485A (enExample) 2009-09-03 2015-08-28 Hoffmann La Roche
JP5947727B2 (ja) 2010-01-20 2016-07-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節
EP2525813B1 (en) 2010-01-20 2017-01-04 Merck Sharp & Dohme Corp. Anti-ilt5 antibodies and ilt5-binding antibody fragments
CN107693791B (zh) 2010-02-26 2022-06-07 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
CA2798390A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
KR20130066632A (ko) 2010-05-06 2013-06-20 노파르티스 아게 치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 항체에 대한 조성물 및 사용 방법
US20130136733A1 (en) 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
MX351027B (es) 2010-12-06 2017-09-28 Seattle Genetics Inc Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer.
JP5885926B2 (ja) * 2011-01-28 2016-03-16 シスメックス株式会社 関節リウマチの存在の評価方法およびその方法に用いられるバイオマーカーセット
BR112013021725A2 (pt) * 2011-02-28 2016-11-01 Genentech Inc marcadores biológicos e métodos para prever resposta aos antagonistas de células b
CA2854457A1 (en) 2011-11-04 2013-05-10 David Jenkins Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
MX2014009490A (es) 2012-02-10 2014-08-29 Novo Nordisk As Metodos relacionados con el tratamiento de enfermedades y trastornos inflamatorios.
WO2013135789A1 (en) * 2012-03-15 2013-09-19 Universiteit Hasselt Means and methods for the determination of the joint destruction progression rate in rheumatoid arthritis patients
WO2013164440A1 (en) 2012-05-03 2013-11-07 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
WO2014028374A1 (en) * 2012-08-17 2014-02-20 Eli Lilly And Company Biomarkers predictive of rheumatoid arthritis or systemic lupus erythematosus response to anti-baff antibody therapy
US20150376701A1 (en) * 2013-01-31 2015-12-31 The University Of Birmingham Biomarkers of autoimmune and/or chronic diseases associated with joint inflammation
EP2813850A1 (en) * 2013-06-10 2014-12-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting rheumatoid arthritis treatment response
KR101664966B1 (ko) * 2013-06-21 2016-10-11 가톨릭대학교 산학협력단 류마티스 관절염 활성도 평가용 바이오마커
AR096687A1 (es) 2013-06-24 2016-01-27 Genentech Inc Anticuerpos anti-fcrh5
CN103399147B (zh) * 2013-08-07 2015-06-17 苏州大学 多聚半乳糖醛酸的新应用
KR101628035B1 (ko) * 2013-09-13 2016-06-09 인제대학교 산학협력단 Ｖｓｉｇ４를 이용한 난소암 치료제 스크리닝 방법
CN103513040B (zh) * 2013-10-16 2015-03-11 常晓天 蛋白cd38在制备类风湿性关节炎诊断标记物中的应用
EP2863231A1 (en) * 2013-10-17 2015-04-22 Institut D'Investigaciones Biomédiques August Pi i Sunyer Diagnostic method for detecting a GABA(A) related autoimmune disease and related subject-matter
CN109207580B (zh) 2014-03-12 2022-03-11 西奈山伊坎医学院 鉴定处于慢性损伤风险的肾异体移植物接受者的方法
RU2554755C1 (ru) * 2014-05-26 2015-06-27 Федеральное бюджетное учреждение науки "Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера" (ФБУН НИИ эпидемиологии и микробиологии имени Пастера) Способ диагностики ревматоидного артрита
WO2015200887A2 (en) 2014-06-26 2015-12-30 Icahn School Of Medicine At Mount Sinai Method for diagnosing subclinical and clinical acute rejection by analysis of predictive gene sets
KR20160048442A (ko) * 2014-10-24 2016-05-04 가톨릭대학교 산학협력단 류마티스 관절염 관련 바이오마커
US20180024142A1 (en) * 2015-01-29 2018-01-25 Ares Trading S.A. Immunoassays for high positively charged proteins
CN105988009B (zh) * 2015-02-28 2018-03-13 复旦大学附属华山医院 Netrin‑4在制备检测胃癌及预后标志物的制剂中的用途
US20180120329A1 (en) * 2015-03-25 2018-05-03 La Jolla Institute For Allergy And Immunology Cxcl13 as an indicator of germinal activity and immune response
WO2016183310A1 (en) * 2015-05-12 2016-11-17 Steere Allen C Autoantigens for diagnosis of rheumatoid arthritis
MA42428B1 (fr) * 2015-06-16 2023-10-31 Hoffmann La Roche Anticorps humanisés et à maturation d'affinité dirigés contre fcrh5 et méthodes d'utilisation
CN105200159B (zh) * 2015-11-06 2018-06-15 北京致成生物医学科技有限公司 骨性关节炎诊疗试剂及其应用
GB201521357D0 (en) * 2015-12-03 2016-01-20 Univ Liverpool Methods for predicting response to anti-TNF therapy
MA45324A (fr) 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
WO2017181038A1 (en) * 2016-04-15 2017-10-19 Rowan University Serum biomarkers for predicting and evaluating response to tnf inhibitor therapy in rheumatoid arthritis patients
US20170321286A1 (en) * 2016-05-05 2017-11-09 Exact Sciences Corporation Detection of lung neoplasia by amplification of rna sequences
US10908159B2 (en) 2016-06-07 2021-02-02 The General Hospital Corporation Identification of a T cell epitope of Prevotella copri that induces T cell responses in patients with Rheumatoid arthritis
RU2622597C1 (ru) * 2016-07-05 2017-06-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КубГМУ Минздрава России) Способ прогнозирования суставного болевого синдрома у пациентов с признаками дисплазии соединительной ткани
GB201616557D0 (en) * 2016-09-29 2016-11-16 Secretary Of State For Health The Assay for distinguishing between sepsis and systemic inflammatory response syndrome
CN106526196B (zh) * 2016-10-08 2018-08-10 北京大学人民医院 Sr-a作为类风湿关节炎诊断标志物及干预靶点的应用
KR102049987B1 (ko) * 2016-11-09 2019-11-28 아이씨엠 주식회사 Nkx3.2 단편 및 이를 함유하는 약학 조성물
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
KR102588627B1 (ko) * 2017-03-08 2023-10-16 김성진 Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법
WO2018164507A2 (ko) * 2017-03-08 2018-09-13 주식회사 길로 Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법
US11325969B2 (en) * 2017-08-29 2022-05-10 Veritas Therapeutics Inc. FGL2 antibodies and binding fragments thereof and uses thereof
CA3036161C (en) * 2017-11-13 2023-03-28 The Multiple Myeloma Research Foundation, Inc. Integrated, molecular, omics, immunotherapy, metabolic, epigenetic, and clinical database
JP7652566B2 (ja) * 2018-01-24 2025-03-27 ジェネンテック， インコーポレイテッド 関節リウマチ（ｒａ）の処置のための診断方法及び治療方法
CN108359726B (zh) * 2018-02-28 2020-09-04 固安博健生物技术有限公司 Coro2b作为分子诊治标志物的用途
EP3765634A4 (en) 2018-03-16 2021-12-01 Scipher Medicine Corporation METHODS AND SYSTEMS FOR PREDICTING THE RESPONSE TO ANTI-TNF THERAPIES
JP7464279B2 (ja) 2018-04-16 2024-04-09 アイカーン スクール オブ メディスン アット マウント シナイ レシピエント血液における移植前トランスクリプトームシグネチャーを使用した急性拒絶反応および腎臓同種異系移植喪失の予測のための方法およびキット
US20190336585A1 (en) * 2018-05-03 2019-11-07 John Lawrence Mee Method for sustainable human cognitive enhancement
US20190359985A1 (en) * 2018-05-22 2019-11-28 John Lawrence Mee Adjustable method for sustainable human cognitive enhancement
CN109142729B (zh) * 2018-06-14 2021-04-23 郑州大学第一附属医院 一种肺癌标志物抗-hmgb3自身抗体及其应用
US20210284942A1 (en) * 2018-06-21 2021-09-16 Astraveus Microfluidic device and method for processing particles
US20190390193A1 (en) * 2018-06-23 2019-12-26 John Lawrence Mee Reversible method for sustainable human cognitive enhancement
US10723191B1 (en) 2018-07-01 2020-07-28 Softwheel Ltd. In-wheel three-arm suspension for vehicles
CN110917351A (zh) * 2018-09-20 2020-03-27 华中科技大学同济医学院附属同济医院 Mbd2抑制剂在预防和治疗纤维化疾病中的用途
WO2020082090A1 (en) * 2018-10-19 2020-04-23 The Regents Of The University Of Michigan Method for monitoring autoimmune disease
CN109207584A (zh) * 2018-11-01 2019-01-15 固安博健生物技术有限公司 Marco作为早期诊断骨关节炎的分子标志物的应用
WO2020163876A1 (en) * 2019-02-08 2020-08-13 The Regents Of The University Of California Compositions and methods involving layilin
MA55804A (fr) 2019-04-29 2022-04-06 Solent Therapeutics Llc Dérivés de 1,1-dioxyde de 3-amino-4h-benzo[e][1,2,4]thiadiazine en tant qu'inhibiteurs de mrgx2
JOP20210297A1 (ar) 2019-05-08 2023-01-30 Janssen Biotech Inc مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية
GB2603294A (en) 2019-06-27 2022-08-03 Scipher Medicine Corp Developing classifiers for stratifying patients
CN114573663B (zh) * 2019-08-27 2023-08-11 广东菲鹏生物有限公司 瓜氨酸肽及其应用、类风湿关节炎的检测试剂与试剂盒
CN110408590B (zh) * 2019-09-06 2022-10-25 遵义医学院附属医院 一种诱导人间充质干细胞向成骨细胞分化的方法与应用
GB201914079D0 (en) * 2019-09-30 2019-11-13 Univ London Queen Mary Method of predicting requirement for biologic therapy
KR102596937B1 (ko) * 2019-11-07 2023-11-03 가톨릭대학교 산학협력단 류마티스 관절염의 판누스 진단용 바이오마커 및 이의 이용
CN111091909B (zh) * 2019-11-26 2022-05-31 中国信息通信研究院 一种医学影像识别方法和装置
CN113122628B (zh) * 2019-12-30 2023-08-11 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Clec5a基因作为标志物在子宫内膜癌中诊断及治疗的应用
CN115023615A (zh) * 2020-01-10 2022-09-06 私募蛋白质体操作有限公司 确定葡萄糖耐量减低的方法
CN112114126B (zh) * 2020-08-13 2023-03-24 川北医学院 一种系统性红斑狼疮的诊断标志物及其应用
WO2022064163A1 (en) * 2020-09-22 2022-03-31 The Secretary Of State For Defence Apparatus, kits and methods for predicting the development of sepsis
UY39488A (es) 2020-10-28 2022-04-29 Janssen Biotech Inc Composiciones y métodos para modular la inmunidad mediada por la cadena delta gamma
KR20230095113A (ko) 2020-11-04 2023-06-28 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체들과 항-cd79b 항체 약물 접합체들을 이용한 치료를 위한 투약
WO2022098638A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
JP7716473B2 (ja) 2020-11-04 2025-07-31 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
CN112646887B (zh) * 2020-12-23 2023-02-28 广州医科大学附属第五医院 Znf239作为肝癌诊治的靶标
CN112946269B (zh) * 2020-12-29 2022-12-27 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Abca1与cd68作为预后标记物在制备肝癌预后预测试剂盒中的应用
CN113186281B (zh) * 2021-04-02 2023-02-28 广州医科大学附属第五医院 作为肝细胞癌标志物的inava
CN113512582A (zh) * 2021-04-15 2021-10-19 上海鸿准生物医药科技有限公司 Slc22a18在过敏变态反应性疾病与炎症性疾病中的应用
CN113307835B (zh) * 2021-04-21 2022-12-13 南通大学 一种siRNA及其在制备慢性疼痛治疗药物中的应用
KR20240005691A (ko) 2021-04-30 2024-01-12 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약
TW202310871A (zh) 2021-05-14 2023-03-16 美商建南德克公司 用莫蘇妥珠單抗及帕羅托珠單抗維多汀治療ｃｄ２０陽性增生性失調之方法
WO2022264134A1 (en) * 2021-06-13 2022-12-22 Technion Research & Development Foundation Limited Method for determining suitability to anti-tnf alpha therapy
EP4479973A1 (en) * 2022-02-16 2024-12-25 Ampel Biosolutions, LLC Unsupervised machine learning methods
CN114994327B (zh) * 2022-04-12 2025-04-15 浙江大学医学院附属第二医院 一种生物标志物gsdme的应用
EP4619005A2 (en) * 2022-11-18 2025-09-24 The United States Government As Represented By The Department Of Veterans Affairs Methods for treating rheumatoid arthritis using a syndecan-1 inhibitor or a syntenin-1 inhibitor
CN116144761A (zh) * 2023-02-24 2023-05-23 山西医科大学 一种类风湿性关节炎诊断分类器的构建方法及其应用
CN116064784A (zh) * 2023-03-23 2023-05-05 上海市光华中西医结合医院 Fgf10在制备检测类风湿性关节炎试剂盒中的应用
JP2024179174A (ja) * 2023-06-14 2024-12-26 シスメックス株式会社 膜性腎症患者に対する化学療法の奏効性に関する情報を取得する方法、膜性腎症患者に対する化学療法の奏効性の判定を補助する方法及び試薬キット
TWI901424B (zh) * 2023-11-10 2025-10-11 長庚醫療財團法人林口長庚紀念醫院 抗-pdgfrl中和抗體在治療關節炎上的用途
CN117567626B (zh) * 2024-01-15 2024-04-26 北京大学人民医院 一种抗瓜氨酸化清道夫受体a多肽抗体及其在制备诊断类风湿关节炎的产品中的应用
WO2025184328A1 (en) * 2024-02-28 2025-09-04 Acurex Biosciences Corporation Polypeptides binding to miro1
WO2025218746A1 (en) * 2024-04-17 2025-10-23 Sinomab Bioscience Limited Methods of treating rheumatoid arthritis
CN119424633B (zh) * 2024-11-07 2025-07-25 浙江赛尔共银生物科技有限公司 一种包含间充质干细胞治疗退行性关节炎的组合物及其制备方法

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434227A (en) * 1982-02-08 1984-02-28 Abbott Laboratories Immunoassay for class specific immunoglobulin antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA1261257A (en) 1984-09-19 1989-09-26 Helgi Valdimarsson Prognostic value of rheumatoid factor isotypes and their association with disease activity
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5484892A (en) 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US6139832A (en) * 1995-02-08 2000-10-31 Human Genome Sciences, Inc. Leukocyte adhesion inhibitor-1 (LAI-1) Polypeptides
AU1916795A (en) 1995-02-08 1996-08-27 Human Genome Sciences, Inc. Human chemokine beta-11 and human chemokine alpha-1
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU723891B2 (en) 1995-06-05 2000-09-07 Human Genome Sciences, Inc. Human chemokine beta-11 and human chemokine alpha-1
DE69729283T2 (de) * 1996-03-20 2005-05-25 Immunomedics, Inc. GLYKOSYLIERTE IgG ANTIKÖRPER
EP1577391A1 (en) 1996-10-25 2005-09-21 Human Genome Sciences, Inc. Neutrokine alpha
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
WO1998027114A2 (en) 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
EA200000311A1 (ru) 1997-09-12 2000-10-30 Апотек Р Энд Д Са Новый белок иммунной системы - кау
ES2285786T3 (es) * 1997-10-29 2007-11-16 Otsuka Pharmaceutical Co., Ltd. Composiciones que inhiben la proliferacion de musculo liso y procedimiento para el diagnostico de arteriosclerosis.
US6110695A (en) 1997-12-02 2000-08-29 The Regents Of The University Of California Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
AU2093499A (en) 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
ES2338661T3 (es) 1999-01-07 2010-05-11 Zymogenetics, Inc. Usos terapeuticos de receptores solubles br43x2.
EP2364997A3 (en) 1999-01-15 2012-07-04 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DE60042785D1 (de) 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
HU230583B1 (hu) 1999-08-17 2017-02-28 Biogen Idec Ma Inc. BAFF-receptor (BCMA) alkalmazásai immunszabályozó szerként
DE10041402A1 (de) 2000-08-23 2002-03-14 Morphochem Ag Neue Verbindungen, die Faktor Xa-Aktivität inhibieren
DE60020580T2 (de) * 1999-09-01 2006-04-27 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Zusammensetzungen zur behandlung von autoimmunkrankheiten, die mittel, welche icam-1/lfa-1 interaktionen inhibieren und mittel, welche cd40-cd40-ligande interaktionen inhibieren, enthalten
US7105149B1 (en) * 1999-11-29 2006-09-12 The Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma
ATE361318T1 (de) 2000-05-12 2007-05-15 Amgen Inc Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen
ATE494304T1 (de) 2000-06-16 2011-01-15 Human Genome Sciences Inc Immunspezifisch bindende antikörper gegen blys
CA2418006A1 (en) 2000-08-18 2002-02-28 Dyax Corp. Binding polypeptides for b lymphocyte stimulator protein (blys)
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
CA2428242A1 (en) 2000-11-07 2002-05-16 Zymogenetics, Inc. Human tumor necrosis factor receptor
JP2004533997A (ja) 2001-02-20 2004-11-11 ザイモジェネティクス，インコーポレイティド Ｂｃｍａ及びｔａｃｉの両者を結合する抗体
US6818406B2 (en) * 2001-03-23 2004-11-16 Mayo Foundation For Medical Education And Research Rheumatoid arthritis markers
NZ529267A (en) 2001-05-11 2006-05-26 Amgen Inc Peptides and related molecules that bind to tall-1
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
CA2453995A1 (en) * 2001-08-03 2003-02-20 Genentech, Inc. Tacis and br3 polypeptides and uses thereof
US7256015B2 (en) 2001-09-21 2007-08-14 Amgen Inc. TALL-1 receptor molecules and uses thereof
WO2003035846A2 (en) 2001-10-24 2003-05-01 National Jewish Medical And Research Center Structure of tall-1 and its cognate receptor
WO2003072827A1 (en) * 2001-10-31 2003-09-04 Children's Hospital Medical Center Method for diagnosis and treatment of rheumatoid arthritis
US20030224386A1 (en) * 2001-12-19 2003-12-04 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
AU2003208415B2 (en) 2002-02-14 2009-05-28 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
JP2005526044A (ja) 2002-02-21 2005-09-02 デューク ユニバーシティ 抗ｃｄ２２抗体を使用した治療方法
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
BR0312767A (pt) 2002-07-18 2005-05-03 Perini Fabio Spa Unidade de armazenamento para produtos alongados
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EA021644B1 (ru) 2002-10-17 2015-08-31 Генмаб А/С Человеческое моноклональное антитело против cd20 и его применение
PL212899B1 (pl) 2002-12-16 2012-12-31 Genentech Inc Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku
US6962006B2 (en) 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
SE0300959D0 (sv) 2002-12-19 2003-04-02 Pharmacia Ab Methods for predicting therapeutic response to agents acting on the growth hormone receptor
ES2538469T3 (es) * 2003-06-05 2015-06-22 Genentech, Inc. Terapia de combinación para trastornos de células B
US20050163775A1 (en) 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
IL156495A0 (en) * 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
DE602004030586D1 (de) * 2003-09-15 2011-01-27 Oklahoma Med Res Found Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis
DE102004016437A1 (de) * 2004-04-04 2005-10-20 Oligene Gmbh Verfahren zur Erkennung von Signaturen in komplexen Genexpressionsprofilen
CA2501422C (en) * 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
AR049292A1 (es) 2004-06-04 2006-07-12 Genentech Inc Metodo para tratar lupus con un anticuerpo cd20
WO2006039238A2 (en) 2004-09-30 2006-04-13 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Irta2 antibodies and methods of use
BRPI0516297A (pt) 2004-10-05 2008-09-02 Genentech Inc métodos de tratamento de vasculite e artigos de fabricação
US20070105133A1 (en) * 2005-06-13 2007-05-10 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
BRPI0614183A2 (pt) * 2005-07-25 2011-03-15 Trubion Pharmaceuticals Inc uso de dose única de moléculas de ligação especìficas para cd20
US7842292B2 (en) * 2005-08-09 2010-11-30 Ares Trading S.A. Methods for treating B-cell malignancies using a TACI-Ig fusion molecule
WO2007038501A2 (en) 2005-09-27 2007-04-05 The Feinstein Institute For Medical Research Rheumatoid arthritis markers
AU2006294477A1 (en) * 2005-09-27 2007-04-05 Source Mdx Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
JP2009530699A (ja) 2006-03-15 2009-08-27 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ ロール検出を備えたリモートコントロール型ポインティング技術
GB0607774D0 (en) 2006-04-20 2006-05-31 Renovo Group Plc Medicaments
WO2007124414A2 (en) 2006-04-21 2007-11-01 Centocor, Inc. Cxcl13 antagonists and their use for the treatment of inflammatory diseases
EP1857559A1 (en) 2006-05-16 2007-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting responsiveness to TNF alpha blocking agents
US20080227655A1 (en) * 2006-05-16 2008-09-18 Michael Bevilacqua Assessment of effect of an agent on a human biological condition using rodent gene expression panels
US20070269827A1 (en) * 2006-05-18 2007-11-22 Oklahoma Medical Research Foundation Predicting and Diagnosing Patients With Autoimmune Disease
WO2008156494A1 (en) * 2006-11-03 2008-12-24 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs in combination with monoclonal antibodies for treating immune disorders
CA2668955A1 (en) 2006-11-09 2008-05-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for predicting therapeutic responsiveness to tnf-alpha blocking agents
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
US20080199481A1 (en) 2007-02-21 2008-08-21 Astrazeneca Ab Compounds
US20100273671A1 (en) 2007-03-01 2010-10-28 Universite Catholique De Louvain Method for the determination and the classification of rheumatic conditions
WO2008121940A1 (en) 2007-03-30 2008-10-09 Centocor, Inc. Cxcl13 antagonists and their use for the treatment of inflammatory diseases
TW200902725A (en) * 2007-04-02 2009-01-16 Genentech Inc Biological markers predictive of rheumatoid arthritis response to B-cell antagonists
WO2008132176A2 (en) 2007-04-27 2008-11-06 Universite Catholique De Louvain Method for evaluating the response of an individual to tnf blocking therapy
CN103710458A (zh) 2007-06-08 2014-04-09 比奥根艾迪克Ma公司 预测抗tnf响应性或无响应性的生物标志物
AU2008295292A1 (en) * 2007-09-03 2009-03-12 Protagen Ag Marker sequences for rheumatoid arthritis and use thereof
WO2009102366A2 (en) * 2007-11-19 2009-08-20 Wyeth Expression of orphan gpr64 in inflammatory diseases
US8121883B2 (en) * 2008-02-07 2012-02-21 International Business Machines Corporation Method and system for automatically prioritizing opportunity based customer requirements
SG174992A1 (en) 2009-04-01 2011-11-28 Genentech Inc Anti-fcrh5 antibodies and immunoconjugates and methods of use
IN2012DN02485A (enExample) 2009-09-03 2015-08-28 Hoffmann La Roche

Also Published As

Publication number Publication date
EP2473637A4 (en) 2013-05-01
BR112012004777A2 (pt) 2019-09-24
CN107385034B (zh) 2021-08-17
RU2539112C2 (ru) 2015-01-10
EP2473637B1 (en) 2017-03-29
JP2017000141A (ja) 2017-01-05
MX2012002766A (es) 2012-04-02
RU2014145058A (ru) 2016-05-27
US8728730B2 (en) 2014-05-20
JP2021019594A (ja) 2021-02-18
RU2012112822A (ru) 2013-10-10
CN107385034A (zh) 2017-11-24
JP5996429B2 (ja) 2016-09-21
WO2011028945A1 (en) 2011-03-10
EP2473637A1 (en) 2012-07-11
CN102597268A (zh) 2012-07-18
US20140341887A1 (en) 2014-11-20
KR20120104517A (ko) 2012-09-21
US20110052488A1 (en) 2011-03-03
CN102597268B (zh) 2017-09-22
CA2772929A1 (en) 2011-03-11
EP3211094A2 (en) 2017-08-30
HK1245341A1 (zh) 2018-08-24
JP6895718B2 (ja) 2021-06-30
IN2012DN02485A (enExample) 2015-08-28
JP2013503643A (ja) 2013-02-04
EP3211094A3 (en) 2017-11-01
US9822400B2 (en) 2017-11-21

Similar Documents

Publication Publication Date Title
MX353186B (es) Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
WO2010036960A8 (en) Methods for treating, diagnosing, and monitoring lupus
PH12018500045A1 (en) Compositions and methods for treating and diagnosing asthma
EP3839068A3 (en) Methods for treating, diagnosing, and monitoring lupus
MX353143B (es) Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.
MX2013000917A (es) Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
EA201390762A1 (ru) Новые биомаркеры для предсказания исхода противораковой иммунотерапии
WO2013033627A3 (en) Diagnosis and treatment of arthritis using epigenetics
AU2011260390A8 (en) Means and methods for diagnosing pancreatic cancer in a subject
MY162933A (en) Chemical compounds
GB2535034A (en) Methods and systems for microbiome characterization, monitoring and treatment
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
MX358541B (es) Metodos para predecir el riesgo de desarrollar hipertension.
EA201491151A1 (ru) Соединения, ингибирующие металлоферменты
EA201390704A1 (ru) Соединения, ингибирующие металлоферменты
EP3486657A3 (en) Means and methods for diagnosing pancreatic cancer in a subject
EA201490832A1 (ru) Биомаркеры, имеющие прогностическое значение в отношении ответа на лечение активатором альфа 7 никотиновых ацетилхолиновых рецепторов
MX2010005395A (es) Metodo para tratar artritis.
GB0915510D0 (en) Method of assessing hydrocarbon source rock candidate
WO2012019000A3 (en) Biomarkers for the identification monitoring and treatment of ovarian cancer
HK1197085A1 (en) Genetic variants for predicting risk of breast cancer
BR112015013771A2 (pt) biomarcador preditivo de resposta ao tratamento de ativador do receptor alfa 7 nicotínico de acetilcolina
WO2011047058A3 (en) Assay for the prediction of therapeutic effectiveness of mesenchymal stromal cells, and methods of using same
IN2012DN00852A (enExample)
WO2011106785A3 (en) Methods of identifying agents effective to treat cognitive decline and diseases associated therewith